JCOG

The Japan Clinical Oncology Group (JCOG) is the largest Japanese cooperative group funded primarily by the National Cancer Center Research and Development Fund.

UOSG:Urologic Oncology Study Group / Publications

更新日:2013年11月8日

a. 論文

1. 委員会承認の治療研究

F Kunieda, H Kitamura, M Niwakawa, et al.: Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection; Japan Clinical Oncology Group Study JCOG 1019. Jpn J Clin Oncol. 2012;42:1094-8. (PMID: 22952293).

2. グループ代表者管理の治療研究

A Yokomizo, K Tobisu, H Kawamoto, et al.: Randomized Controlled Trial to Evaluate Radiation plus Endocrine Therapy or Endocrine Therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol. 35: 34-36, 2005.
Y Matsui, H Nishiyama, O Ogawa, et al.: The current status of perioperative chemotherapy for invasive bladder cancer : a multiinstitutional retrospective study in Japan. Int J Clin Oncol, 10: 133-138, 2005.
K Kawamoto, H Enokida, M Nakagawa, et al.: p16 (INK4a) and p14 (ARF) methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 339: 790-796, 2006.
I Honma, N Masumori, T Tsukamoto, et al.: Removal of more lymph nodes may provide a better outcome as well as more accurate pathology in patients with bladder cancer-An analysis of the role of pelvic lymph node dissection, Urology. 68:543-548, 2006.
A Yokomizo, M Murai, S Baba, et al.: Percentage of positive biopsy cores, preoperative prostate-specific antigen(PSA) level, pT and Gieason score as predictors of PSA recurrence after radical prostatectomy; a multi-institution outcome study in Japan. BJU Int. 98:549-553,2006.
Y Kakehi, T Kamoto, T Shiraishi, et al.:Prospective Evaluation of Selection Criteria for Active Surveillance in Japanese Patients with Stage T1c N0 M0 Prostate Cancer. Jpn J Clin Oncol. 38 (2):122-128, 2008.
T Shindo, N Masumori, F Fukuta, et al.: Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease? Jpn J Clin Oncol. 40:153-156, 2010.
K Kuroiwa, T Shiraishi, O Ogawa, et al.: for the Clinicopathological Research Group for Localized Prostate Cancer Investigators: Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol. 183 (3): 952-957, 2010.
H Koga, S Ozono, T Tsushima, et al. BCG Tokyo Strain Study Group: Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol. 17 (9): 759-767, 2010.
S Hinotsu, H Akaza, S Naito, et al.: Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence?free survival following transurethral resection of bladder tumor for non-muscle-invasive bladder cancer. BJU International. 108: 187-193, 2011.
T Maeda, E Kikuchi, K Matsumoto, et al. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. J Urol. 185: 802-806, 2011.
S Sakano, H Matsuyama, et al.: Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines. BJU International. 107: 1598-1604, 2011.
K Yuge, E Kikuchi, K Matsumoto,et al.: Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy. Jpn J Clin Oncol. 41: 565-570, 2011.
H Kitamura, K Taguchi, Y Kunishima, et al.: Paclitaxel, ifosmide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phse II study of the SUOC group. Cancer Sci. 102: 1171-1175, 2011.
H Tsuruta, T Inoue, S Narita, et al.: Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma. Int J Clin Oncol. 16: 533-538, 2011.
M Ikeda, K Matsumoto, K Tabata, et al.: Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Jpn J Clin Oncol. 41: 1214-1220, 2011.
M Sugimoto, T Shiraishi, H Tsunemori, et al.: Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort. Jpn J Clin Oncol. 40(10):973-979, 2010.
Y Sumiyoshi, K Hashine, Y Kakehi, et al.: Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study. Jpn J Clin Oncol. 40(10):967-972, 2010.
F Fukuta, N Masumori, I Honma, et al.: Clinical Outcomes of Patients with pT0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience. Jpn J Clin Oncol. 2011;41:115-20. (PMID: 20696818)
M Bul, X Zhu, R Valdagni, et al.: Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013 Apr;63(4):597-603.

3. 附随研究等

X Wu, Y Kakehi, et al.: Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol. 174: 2138-2143, 2005.
A Yokomizo, M Murai, S Baba, et al.: Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int. 98:549-553, 2006.
N Nishiyama, E Arai, R Nagashio, et al.: Copy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterations. Cacinogenesis. 32: 462-469, 2011.
H Okazoe, X Zhang, D Liu, et al.: Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder. Int J Mol Sci. 2013 Jun 10;14(6):12367-12379.

4. 総説・解説

S Naito: Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer. Jpn J. Clin Oncol. 35:365-374, 2005.
H Kitamura, T Tsukamoto.: Early bladder cancer: concept, diagnosis,and management. Int J Clin Oncol. 11: 28-37, 2006.
塚本泰司、前田俊浩、福多史昌:筋層浸潤膀胱癌におけるneoadjuvant chemotherapyの意義.泌尿器外科.20:1137-1145, 2007.
筧 善行: 特集 リスクで考える前立腺癌治療 リスクで考える各種治療法の適応と限界 PSA監視療法. Urology View. 8(2):27-32, 2010.
横溝 晃、内藤誠二: 前立腺がん根治術後再発に対する治療. 臨牀と研究. 88 (11): 1398-1402, 2011.
Y Kakehi. Re: Prostate cancer antigen 3 score accurately predicts tumor volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 60: 178-179, 2011.
Y Kakehi: Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes. Asian J Androl. 14(3):361-364, 2012.
M Sugimoto, Y Kakehi: Updated results from the European Randomized Study of prostate-specific antigen (PSA) screening for prostate cancer: are Asian countries encouraged to promote PSA screening? Asian J Androl. 14(4): 522-524, 2012.
北村 寛:膀胱がんに対する術前補助化学療法の意義は? 臨床腫瘍プラクティス 2012;8:155-8.

b. 主な学会発表

1. 委員会承認の治療研究

横溝 晃、古賀寛史、此元竜雄、他:早期前立腺がんにおける根治術後の再発に関するoutcome study. 第41回日本癌治療学会総会. 2003年10月.
塚本泰司、他:筋層浸潤癌に対する根治的膀胱摘除の手術所見と術後早期合併症の検討-JCOG 0209試験の結果-. 第49回日本癌治療学会学術集会. 2011年10月.
北村 寛、塚本泰司、舛森直哉、他:筋層浸潤性膀胱癌に対する術前MVAC療法後の病理所見-JCOG0209試験. 第50回日本癌治療学会学術総会. 2012年10月. 横浜.
H Kitamura, T Tsukamoto, N Masumori, et al.: Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for invasive bladder cancer (BC): Japan Clinical Oncology Group Study, JCOG0209. ASCO Genitourinary Cancers Symposium 2013, Feb 2013, Orlando, FL
>H Kitamura, T Tsukamoto, N Masumori, et al.: Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group Study, JCOG0209. ASCO ’13 Annual Meeting, Jun 2013, Chicago, IL
二瓶圭二、横溝 晃、内藤誠二、他:JCOG0401前立腺癌術後PSA再発臨床試験における放射線治療QA. 第25回日本放射線腫瘍学会(東京). 2012年11月.

2. グループ代表者管理の治療研究

S Naito: Treatment of Patients with PSA Recurrence after Radical Prostatectomy. The 18th International Symposium of Foundation for Promotion of Cancer Research. Jan 2005.
Y Kakehi, T Kamoto, T Shiraisi, et al.: PSA doubling time assessment based upon 4 consecutive measurements for 6 months: Is it a realistic strategy to spare over-treatment for patients with stage T1c prostate cancer presenting favorable biopsy features? Annual American Urological Association Meeting. May 2006.
横溝 晃、古賀寛史、鳶巣賢一、他:日本の早期前立腺がん根治手術後の再発に関するアウトカム研究 第93回日本泌尿器科学会総会. 2005年4月.
M Sugimoto, T Shiraishi, H Tsunemori, et al.: Predictability of PSA doubling time for unfavorable pathology at radical prostatectomy: Results from a prospective Japanese active surveillance cohort. EAU Annual Congress. Mar 2011.
M Sugimoto, H Hirama, Y Kakehi, PRIAS-JAPAN Study Group: Evaluation of prostate re-biopsy outcomes and change in QOL status at 1-year after active surveillance in Japanese prostate cancer patients-From a Japanese AS study and the PRIAS-JAPAN-. EAU Annual Congress. Mar 2012.
M Sugimoto, H Hirama, Y Kakehi, et al.:前立腺癌PSA監視療法における1年目の再生検の結果とQOLの変化について. -日本の2つの多施設前向き研究での検討-. 第10回日本臨床腫瘍学会. 2012年7月.
杉元幹史、平間裕美、上田修史、他: PSA監視療法中の1年目再生検における病理所見悪化予測因子の検討 -PRIAS-JAPAN-. 第101回日本泌尿器科学会総会. 2013年4月.

3. 附随研究等

なし  

4. 総説・解説

なし